-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
PharmaTher Provides Business Highlights And Releases Audited Annual Financials
PharmaTher Provides Business Highlights And Releases Audited Annual Financials
PharmaTher Holdings Ltd. (OTCQB:PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.
The company, which focuses on delivering ketamine for treating mental health disorders closed the annual period as follows:
-
Cash and cash equivalents totaled $6.684.912, compared to $2.028.554 as of May 31, 2022.
-
Investment reached $2.166.260, somewhat less than the gathered $2.263.620 as of May 31, 2021.
-
R&D annual expenses for a total of $1.902.274, an almost 250% increase of the $548.770 yearly invested in the prior period.
-
Net loss for the annual period ending May 31, 2022, was $2.928.566.
As for research, partnerships, pipeline development and commercialization, PharmaTher has stayed quite busy in recent months.
The company presented positive efficacy and safety data from its Phase 1/2 clinical trial of ketamine as treatment of levodopa-induced dyskinesia in Parkinson's disease as well as for its IND-enabling study of proprietary LSD and psilocybin microneedle patches.
In its legal search, it obtained FDA approval for its IND application for ketamine to treat amyotrophic lateral sclerosis (ALS), orphan drug designations for ketamine to treat complex regional pain syndrome and status epilepticus, and is currently seeking the agency's approval for its ketamine injection and infusion products for anesthesia and procedural sedation.
Lastly, PharmaTher signed several development agreements. One was with CCBIO for its novel ketamine wearable delivery technology, another with LTS Lohmann for its ketamine microneedle patch, and a latter with Alcami for the clinical and commercial manufacturing of ketamine.
The company has also achieved full funding for its ketamine development programs, including injection and infusion products, a microneedle patch and a wearable delivery device.
PharmaTher's CEO, Fabio Chianelli, believes the company has achieved important clinical and business milestones this fiscal year, and that will pave the way towards becoming a commercial-stage firm next year.
Chianelli explained that in order to support the commercial objectives, the company aims "to file abbreviated new drug applications with the FDA for our ketamine injectable products for anesthesia and procedural sedation," expecting to get the approvals by the second half of 2023.
PharmaTher's clinical development objectives for the next twelve months include obtaining FDA green light to conduct a Phase 3 trial studying ketamine for Parkinson's, presenting results from the Phase 2 trial of ketamine for Amyotrophic Lateral Sclerosis (ALS), presenting clinical study results in depression and pain with proprietary ketamine microneedle patch and ketamine wearable pump device, as well as partnering with other pharma companies for PharmaTher's ketamine products, drug delivery systems and clinical programs.
Photo courtesy of Pexels.
PharmaTher Holdings Ltd. (OTCQB:PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.
PharmaTher控股有限公司(场外交易代码:PHRRF)已经出版了它的运营和经审计的财务结果为截至2022年5月31日的财年。
The company, which focuses on delivering ketamine for treating mental health disorders closed the annual period as follows:
该公司专注于提供用于治疗精神健康障碍的氯胺酮,其年度结束期如下:
-
Cash and cash equivalents totaled $6.684.912, compared to $2.028.554 as of May 31, 2022.
-
Investment reached $2.166.260, somewhat less than the gathered $2.263.620 as of May 31, 2021.
-
R&D annual expenses for a total of $1.902.274, an almost 250% increase of the $548.770 yearly invested in the prior period.
-
Net loss for the annual period ending May 31, 2022, was $2.928.566.
-
现金和现金等价物总计6.684.912美元,而截至2022年5月31日为2.028.554美元。
-
投资达到2.166.260美元,略低于截至2021年5月31日的2.263.620美元。
-
研发年度费用总计1.902.274美元,增长近250%在前一时期每年投资的548.770美元中。
-
净亏损截至2022年5月31日的年度期间为2.928.566美元。
As for research, partnerships, pipeline development and commercialization, PharmaTher has stayed quite busy in recent months.
至于研究、合作、流水线开发和商业化,PharmaTher留了下来很忙最近几个月。
The company presented positive efficacy and safety data from its Phase 1/2 clinical trial of ketamine as treatment of levodopa-induced dyskinesia in Parkinson's disease as well as for its IND-enabling study of proprietary LSD and psilocybin microneedle patches.
该公司提交了氯胺酮治疗帕金森病左旋多巴诱导的运动障碍的1/2期临床试验的阳性疗效和安全性数据以及其支持IND的研究专有LSD和裸盖菇素微针贴片.
In its legal search, it obtained FDA approval for its IND application for ketamine to treat amyotrophic lateral sclerosis (ALS), orphan drug designations for ketamine to treat complex regional pain syndrome and status epilepticus, and is currently seeking the agency's approval for its ketamine injection and infusion products for anesthesia and procedural sedation.
在其法律搜索中,它获得了FDA批准用于治疗肌萎缩侧索硬化症(ALS)的氯胺酮的IND申请,以及用于治疗复杂区域疼痛综合征和癫痫持续状态的氯胺酮的孤儿药物名称,目前正在寻求该机构对其用于麻醉和程序镇静的氯胺酮注射和输注产品的批准。
Lastly, PharmaTher signed several development agreements. One was with CCBIO for its novel ketamine wearable delivery technology, another with LTS Lohmann for its ketamine microneedle patch, and a latter with Alcami for the clinical and commercial manufacturing of ketamine.
最后,PharmaTher签署了几个发展协议。其中一个是和CCBIO由于其新颖的氯胺酮可穿戴式递送技术,另一款具有LTS罗曼前者用于氯胺酮微针贴片,后者用于临床和商业生产氯胺酮。
The company has also achieved full funding for its ketamine development programs, including injection and infusion products, a microneedle patch and a wearable delivery device.
该公司还为其氯胺酮开发项目实现了全额资金,包括注射和输液产品、微针贴片和可穿戴递送设备。
PharmaTher's CEO, Fabio Chianelli, believes the company has achieved important clinical and business milestones this fiscal year, and that will pave the way towards becoming a commercial-stage firm next year.
PharmaTher首席执行官法比奥·奇亚内利,相信该公司在本财年取得了重要的临床和业务里程碑,并将为明年成为一家商业舞台公司铺平道路.
Chianelli explained that in order to support the commercial objectives, the company aims "to file abbreviated new drug applications with the FDA for our ketamine injectable products for anesthesia and procedural sedation," expecting to get the approvals by the second half of 2023.
Chianelli解释说,为了支持商业目标,该公司的目标是“为我们用于麻醉和程序镇静的氯胺酮注射产品向FDA提交简短的新药申请”,预计在2023年下半年获得批准。
PharmaTher's clinical development objectives for the next twelve months include obtaining FDA green light to conduct a Phase 3 trial studying ketamine for Parkinson's, presenting results from the Phase 2 trial of ketamine for Amyotrophic Lateral Sclerosis (ALS), presenting clinical study results in depression and pain with proprietary ketamine microneedle patch and ketamine wearable pump device, as well as partnering with other pharma companies for PharmaTher's ketamine products, drug delivery systems and clinical programs.
PharmaTher的临床发展目标在接下来的12个月里,包括获得FDA的许可,进行用于帕金森氏症的氯胺酮的第三阶段试验,展示用于肌萎缩侧索硬化症(ALS)的氯胺酮的第二阶段试验的结果,展示使用专有的氯胺酮微针贴片和氯胺酮可穿戴泵设备治疗抑郁症和疼痛的临床研究结果,以及与其他制药公司合作开发PharmaTher的氯胺酮产品、药物输送系统和临床方案。
Photo courtesy of Pexels.
照片由Pexels提供。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧